Barclays reiterates an 'Overweight' on Halozyme Therapeutics (NASDAQ: HALO), PT $12.

Barclays analyst says, "We would be buyers of HALO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE